Velavigo Shanghai Pharmaceutical

VelaVigo is a clinical-stage biopharmaceutical company headquartered in Nanjing, China, with significant research and development operations in Shanghai. The company focuses on the discovery and development of innovative antibody-based immunotherapies for oncology, leveraging its proprietary V-Lable platform to create a diverse pipeline of monoclonal and bispecific antibodies. Its lead candidate, LBL-007, is a LAG-3 monoclonal antibody currently undergoing Phase 2 clinical trials for various solid tumors. VelaVigo has established strategic collaborations with major industry players like Innovent Biologics to advance its therapeutic programs. The company's pipeline also includes novel candidates targeting TIM-3, TNFR2, and bispecific constructs like PD-L1/4-1BB. With a strong emphasis on R&D, VelaVigo aims to address unmet medical needs in cancer treatment through the development of first-in-class and best-in-class biologics.